TomoTherapy (TOMO) Responds to Letter From Avalon Capital

November 18, 2008 3:29 PM EST

TomoTherapy Incorporated (NASDAQ: TOMO) confirmed receipt of a letter dated November 17, 2008, from Avalon Capital and issued the following statement from TomoTherapy's Board of Directors:

"We appreciate constructive input from all of our shareholders, we take Avalon's views seriously and we are committed to acting in the best interests of all shareholders. The Board continues to be actively engaged with management on a strategic plan to address business challenges and opportunities to maximize the potential of our technology and products, which Avalon has rightly recognized produce better treatment plans and clinical outcomes for patients. The Board fully recognizes its fiduciary duty to shareholders."

The Board noted a number of material misstatements in Avalon's letter. Among other things, Avalon was in fact offered the opportunity to meet directly with several independent directors, but Avalon did not agree to the meeting. The invitation to meet remains open. Moreover, with respect to recent by-law amendments, the Board noted that it approved a shareholder-friendly declassification of the Board.

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy(R) Hi·Art(R) treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers.[SM]

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?